To curtail the neurotoxic effects of KP metabolism, as is required in AD, HD, MS, epilepsy and depression, therapeutic inhibition of oxidative KP enzymes may provide benefit, while development of drugs that act at important metabolic junctions could be developed to alter metabolite ratios. This evidence concerns the gene NPPA and Huntington disease.